Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. - Wikidata - awgldk - TriplyDB

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

http://www.wikidata.org/entity/Q39796383

about

Molecular biology of lung cancer: clinical implications Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia?Targeting Notch to overcome radiation resistance γ-Secretase inhibitors and modulators.Targeting γ-secretase in breast cancer Notch signalling pathway as an oncogenic factor involved in cancer development Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma Notch inhibition as a promising new approach to cancer therapy.Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin.Current views on the role of Notch signaling and the pathogenesis of human leukemia.miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma Notch inhibitors for cancer treatment.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Notch signaling in pediatric soft tissue sarcomas Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.Systematic identification of signaling pathways with potential to confer anticancer drug resistance.Investigational Notch and Hedgehog inhibitors--therapies for cardiovascular disease.Differential levels of Neurod establish zebrafish endocrine pancreas cell fates.Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy.First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell mass.Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.Targeted therapies for lung cancer: clinical experience and novel agents Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.Gamma secretase inhibitors of Notch signaling A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma.A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition

P2860

Q24610335-7B5FD547-9229-4C42-A589-BBE811C82338 Q26766395-A439FA56-C909-4AE9-B20F-46B8BD66FCE5 Q26771701-BC4C7350-C554-4E5C-8EE6-828A39DD5FFB Q26830462-F1E677D5-F3C3-4CF5-AE1B-7DAC38D6042E Q27001056-FF52579A-1354-451D-A685-849972C6680E Q28072977-FE382028-853D-4EAE-85B3-6E2E7CEFAA32 Q28080187-13F632EA-AA9C-49C7-B6F9-DFEC4576C3C1 Q28396304-8394E001-2091-40BF-BBE0-DB25B93EF738 Q28477769-0F520AFB-610A-4C02-885F-78F2694B43ED Q28744417-2D7712AA-3380-467D-BF32-DF9BAF1CE97F Q30426785-3D8EEEBE-2674-42C4-BE70-8716717B34E7 Q30426842-B9DE48A8-A38A-4240-8546-363E59E349F5 Q30434130-F381E59B-C25B-485E-8C6E-5B66C7230B89 Q33400889-06EBAF7E-79E8-49E9-B9DD-D0F1AE808513 Q33759792-6364FB3C-008D-41F3-81A1-AF51F1ADBEDA Q34086641-4C859150-9F84-4151-BC8A-0C04AC0D33CD Q34123719-05B1EE8E-0851-45E3-83A5-730F96177569 Q34330869-F07F438E-E59F-4A08-9829-77B162F6E5DF Q34404209-4E3F93B6-D5C2-4A4D-BD24-6145932CAEDF Q34480012-2515CC16-5CE2-4BAE-8554-43E0F4ABA14A Q34543713-83CAD904-54A1-4B11-A27F-ACC3AE6034F3 Q34706060-8119AAED-1DBD-49F6-8EE4-8EF63131274F Q34978436-0D3C265F-5960-4922-9F1C-667E976B281B Q35159023-3A322927-430E-4F06-8706-A2E4EFD006F2 Q35603713-359DDE90-3150-4B23-AB75-8C19ACE05D37 Q35612318-D38F348D-35D9-484C-9692-05AB0F33BA8B Q35748649-62439930-68BE-455C-A8AD-BDF70C10FA6E Q35945915-AD596BBB-1E9B-4294-9F9B-0A7D22D3708D Q35947964-EE1B60CA-D4FC-4978-8A0C-8E73D5DB7628 Q35985276-96F239B6-A5E0-4F0D-9176-59B6C2EB225F Q36024533-5785EA33-E176-47BB-BFE1-E4F1911FAA35 Q36054970-406FA3ED-48A4-4EC5-B325-421D0FA99848 Q36499901-37CB11F4-5BD7-46AB-9BE2-134D2EC85A6B Q36861775-4D6D082F-E65E-484C-919F-606C0F8265F3 Q37013225-75FAE1F4-8BE8-4FEE-AB92-E4540F0CBDC7 Q37053722-1C7EE5CE-3094-41C3-9277-F2495CEBD15F Q37111141-30809D9E-0D90-4068-8DE2-11434E226C1E Q37165664-76B03DA7-F7CF-4B61-A2C9-DAC4E69D668E Q37166379-02543471-63DD-436B-981B-6699F1F87944 Q37169972-6D677C6D-02D9-4381-AEE7-3B09D7973394

P2860

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

http://www.wikidata.org/entity/Q39796383

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Preclinical profile of a poten ...... nd pharmacodynamic properties.

@en

Preclinical profile of a poten ...... nd pharmacodynamic properties.

@nl

type

label

Preclinical profile of a poten ...... nd pharmacodynamic properties.

@en

Preclinical profile of a poten ...... nd pharmacodynamic properties.

@nl

prefLabel

Preclinical profile of a poten ...... nd pharmacodynamic properties.

@en

Preclinical profile of a poten ...... nd pharmacodynamic properties.

@nl

P1433

Q39796383-4E672BF0-FFEE-4CCF-A046-3D0F117C4BB5

P1476

Q39796383-BB72A8E1-8648-4475-9FEF-A83C81907EFB

P2093

Q39796383-04A0339A-68B6-4D08-BC5F-E19E0EAA9F1B

Q39796383-0D5BEB80-45C2-498C-873C-A13D06BFCDCB

Q39796383-38848876-0E3F-4FDB-A87C-A54B7C7528F9

Q39796383-44B627A2-E77D-427D-88E6-3496D8485476

Q39796383-57A0A0C0-891A-4E66-9300-BD987A47C018

Q39796383-5D610192-08BA-4E48-9699-E6EB7E45199B

Q39796383-68463E74-904A-4B6E-A465-865F47955566

Q39796383-739FEE99-D62C-4255-AA2F-8DFD468C5021

Q39796383-78E4C99E-7B24-4BF5-9667-FA0EA2E195A5

Q39796383-82ED4556-E113-4E13-929F-D2DEFC1C57FD

P2860

Q39796383-059D0D9F-BDAB-4A80-9DD7-75DE3FC4D340

Q39796383-062C7C1D-5409-49D7-8037-36C68DDDBB69

Q39796383-1060A40F-1596-4C38-9885-F91DC91DFF64

Q39796383-18703846-BE4E-4839-AE85-136E522D1995

Q39796383-1E2FEF61-B3F5-4F65-B122-2A643A542F29

Q39796383-3891096A-5EF8-4517-A0ED-A9141061857A

Q39796383-39ADB4C0-9C8A-4813-B90A-F97755B10E27

Q39796383-39F5B3EB-A549-4570-AE80-4B8BBE4B4195

Q39796383-4863335E-8F60-43E9-BB15-DB1F1C7D1E21

Q39796383-4B53B36C-21C7-4B28-B2A5-7E0BC9044D77

P304

Q39796383-8AAD2D66-772B-4713-90BE-277AA980ED3B

P31

Q39796383-D562C9C2-DF69-4521-9D8F-5C84810BBB84

P356

Q39796383-611DAC9A-2420-4BC2-B0ED-BC16DB97D870

P407

Q39796383-956A7E6B-ABD6-44F4-A45F-35E83559D5E8

P433

Q39796383-BD3B39A2-3463-422C-B810-34B11BDD8941

P478

Q39796383-81F02C5B-87F0-4802-B358-EE3464875C33

P577

Q39796383-018EA1A4-EA9E-41BD-9C29-11459722B28A

P698

Q39796383-0F00636A-EB89-4ED4-AC1F-456CCCFA5F0E

P932

Q39796383-FC03C01C-C78E-4220-B2BA-A704E1332B69

P356

0008-5472.CAN-09-1843

P1433

Cancer Research

P1476

Preclinical profile of a poten ...... nd pharmacodynamic properties.

@en

P2093

Alexander Flohr

http://www.w3.org/2001/XMLSchema#string

Daisy Carvajal

http://www.w3.org/2001/XMLSchema#string

David Heimbrook

http://www.w3.org/2001/XMLSchema#string

Helmut Jacobsen

http://www.w3.org/2001/XMLSchema#string

Holly Hilton

http://www.w3.org/2001/XMLSchema#string

James Cai

http://www.w3.org/2001/XMLSchema#string

John F Boylan

http://www.w3.org/2001/XMLSchema#string

John Roberts

http://www.w3.org/2001/XMLSchema#string

Kathryn Packman

http://www.w3.org/2001/XMLSchema#string

Kelli Glenn

http://www.w3.org/2001/XMLSchema#string

P2860

Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

Summaries of Affymetrix GeneChip probe level data

Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation

Type V collagen controls the initiation of collagen fibril assembly

Notch inhibitors as a new tool in the war on cancer: a pathway to watch.

Microfibril-associated glycoprotein-2 interacts with fibrillin-1 and fibrillin-2 suggesting a role for MAGP-2 in elastic fiber assembly.

Stem cell origin of cancer and differentiation therapy.

Intramembrane proteolysis: theme and variations.

P304

7672-7680

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-1843

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19773430

http://www.w3.org/2001/XMLSchema#string

P932

5260798

http://www.w3.org/2001/XMLSchema#string